New commitment to Quell in largest ever Series A
New commitment to Quell in Syncona's largest ever Series A financing
11 February 2021
· Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona's total commitment to Quell to £59.3 million
· First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022
· Research programmes initiated in Type 1 Diabetes ("T1D") and Amyotrophic Lateral Sclerosis ("ALS")
Syncona Ltd ("Syncona") announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ("Quell"). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona's total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a 74 per cent fully diluted ownership stake in Quell at the point current commitments are invested.
Quell has been established with the aim of developing engineered Treg cell therapies. Tregs are a subset of T cells found naturally in circulation, with the potential to downregulate the immune system. Quell is seeking to utilise the power of these natural Treg cells to advance therapies for the management and treatment of a range of diseases including solid organ transplant rejection, autoimmune and inflammatory diseases.
The company's first programme is targeting tolerance induction post liver transplantation. Quell has nominated its clinical candidate for this programme and expects to enter the clinic in the first half of 2022. The business has now expanded its pipeline, working in partnership with Syncona to identify and prioritise two promising research programmes for ALS and T1D. The Quell team will advance these programmes in part through its existing collaborations with world leading institutions: the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield and the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), to broaden its focus beyond transplant and continue research in neuroinflammation and autoimmune disease.
The expanded Series A financing will enable Quell to take its first programme into the clinic, progress its research programmes in T1D and ALS, develop a scalable manufacturing process and expand its senior leadership team.
Martin Murphy, CEO of Syncona Investment Management Limited, said: "Quell has made strong progress since its foundation in 2019 moving from concept to clinical candidate nomination in less than 18 months. The business was founded around the work of world-leading academics and has progressed an exciting first-in-class programme targeting tolerance induction post liver transplantation leveraging the expertise in the company.
Syncona has also worked in close partnership with Quell's leading management team to build out a pipeline of promising programmes which we believe could offer patients transformative therapies to resolve chronic diseases. This financing underscores our belief and excitement about Quell's potential to be a global leader in treating liver transplantation as well as autoimmune and inflammatory diseases and we look forward to working closely with the company as it continues to scale."
Iain McGill, Chief Executive of Quell Therapeutics, said : "We have made tremendous progress with our lead programme in liver transplantation over the past twelve months. We have selected our first clinical candidate, QEL-001, and are progressing well through process development. In parallel we have leveraged our Modular Engineered Treg platform to build out a valuable pipeline in autoimmune and neuroinflammatory diseases. We are leading the scientific field in bringing these potentially transformative therapies to patients, with our lead programme expected to be the first multiply engineered Treg therapy to enter the clinic."
Professor Alberto Sanchez-Fueyo, Professor of Hepatology in the Department of Inflammation Biology at Kings College London, said: "Quell is focused on delivering its first programme targeting tolerance induction post liver transplantation into the clinic. This is particularly exciting for me as my passion is to try to understand how the immune responses within the liver are regulated and how we can treat patients without administering lifelong immunosuppression. I think there is a fantastic opportunity with our first product to provide a transformational impact for patients and this funding is critical as we continue to make progress towards that goal."
Professor Elmar Jaeckel, Group Leader of "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School said : "Tregs are vital for the induction and maintenance of peripheral tolerance and are key in preventing excessive immune responses and autoimmunity. Quell is working in close collaboration with its academic partners to ensure we are selecting the best possible targets and therapies in order to build a pipeline that has the potential to fundamentally resolve the treatment of chronic diseases."
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
About Quell Therapeutics:
Quell Therapeutics is a privately held biotechnology company with a vision to become a leading engineered Tregs cell therapy company. The company is developing next generation engineered T regulatory (Treg) cell therapies for a range of diseases of immune dysfunction.
Quell Therapeutics was founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Savannah Energy
- 10 hours ago Buccaneer Energy PLC
- 11 hours ago Savannah Energy
- 11 hours ago Carclo
- 11 hours ago Schroder Japan Growth Fund